Brought to you by 
Lilly to fund Centocor Centoxin development for rights
13 Jul 1999
Executive Summary
Eli Lilly appears to have faith in Centocor's Centoxin despite a setback at the FDA and the crowded field of septic shock products vying for approval within the next 12 months. Lilly is providing $100 million for the rights to market Centoxin.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly to fund Centocor Centoxin development for rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice